Drug intelligence / Profile preview

YFZ-1DJ

Development stage: Unknown
Lead developer: Yifan Pharmaceutical
Administration: Oral

Overview

**YFZ-1DJ** is a traditional Chinese medicine drug candidate developed by Yifan Pharmaceutical for prevention of relapse in people with opioid dependence. Yifan's pipeline identifies the program as having completed a Phase Ib clinical study and targeting subsequent marketing authorization. The active constituents, molecular targets, route of administration, dosage form, and pharmacologic mechanism have not been publicly disclosed. ([yifanyy.com](https://www.yifanyy.com/innovation/pipeline.html))

Beyond the preview

Go deeper on YFZ-1DJ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YFZ-1DJ.

Explore the full profile